Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$2.12 - $4.18 $5,819 - $11,474
-2,745 Reduced 1.74%
154,580 $626,000
Q3 2023

Nov 13, 2023

SELL
$2.66 - $10.04 $18,061 - $68,171
-6,790 Reduced 4.14%
157,325 $423,000
Q2 2023

Aug 11, 2023

BUY
$7.28 - $11.82 $223,168 - $362,342
30,655 Added 22.97%
164,115 $1.53 Million
Q1 2023

May 15, 2023

BUY
$5.21 - $14.05 $828 - $2,233
159 Added 0.12%
133,460 $1.19 Million
Q4 2022

Feb 13, 2023

SELL
$4.69 - $8.36 $1,191 - $2,123
-254 Reduced 0.19%
133,301 $663,000
Q3 2022

Nov 14, 2022

BUY
$5.7 - $8.68 $31,321 - $47,696
5,495 Added 4.29%
133,555 $775,000
Q2 2022

Aug 12, 2022

BUY
$5.04 - $14.05 $155,841 - $434,440
30,921 Added 31.83%
128,060 $708,000
Q1 2022

May 13, 2022

BUY
$8.75 - $14.51 $2,231 - $3,700
255 Added 0.26%
97,139 $1.12 Million
Q4 2021

Feb 08, 2022

BUY
$8.98 - $20.09 $870,018 - $1.95 Million
96,884 New
96,884 $1.23 Million

Others Institutions Holding THRX

About Theseus Pharmaceuticals, Inc.


  • Ticker THRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,713,400
  • Description
  • Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...
More about THRX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.